BeiGene CEO on Covid Collaborations, Regulation, China

The transcript discusses the company's involvement in COVID-19 therapies, changes in the global regulatory environment due to the health crisis, and international collaborations with Amgen and Novartis. It highlights efforts to standardize clinical trials globally and addresses the impact of an aging population on disease prevalence, particularly in China.

What lessons can be learned from the regulatory changes observed during the COVID pandemic?

How does the collaboration with companies like Amgen and Novartis benefit the oncology specialist company?

What are the key factors that have contributed to the success of the oncology industry in the last decade?